Biohaven .(BHVN) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments • Cash, cash equivalents, marketable securities and restricted cash as of October 2, 2024 totaled approximately $642 million • Achieved positive topline trial results from pivotal trial with troriluzole in spinocerebellar ataxia (SCA) ◦ Troriluzole 200 mg QD dosed orally in patients with SCA met the study's primary endpoint on the change from baseline on the modified functional Scale for the Assessment and Ra ...